Oculis Holding AG
NASDAQOCS utilization surges to 92.47%, highest in 52 weeks, as short sellers rush to cover amid stock collapse following failed DIAMOND trials.
Snapshot as of 15 Jul 2026
OCS has fallen another 46% since Friday's trial-failure note — and the Street's response this week tells the real story. The stock closed at $12.29 on Tuesday, down 59% on the week and 55% over the past month. That…
OCS entered the weekend down 23% — a collapse driven by a single late-Friday announcement. The entire OCS story this week resolves to one event. After Friday's close, Oculis reported topline results from the DIAMOND-1…
OCS arrives at Wednesday's Q1 results riding one of the sharpest rallies in its recent history — up 20% over the past month and 16% in the last week alone to $32.65 — making tomorrow's print far more consequential than…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for OCS — free to start on ORTEX.
Sign up for free →Open OCS on ORTEX